Evidence map›Paper›PMID 40904774›Full record

ArticleFrontiers in nutrition2025

Global, regional, and national burden of NASH related liver cancer in adults aged 45 and above: an analysis from the GBD 2021 and forecast to 2050.

Jianing Shi, Xuan Wu, Jiali Yu, Qingli Zhou

Abstract read
In one paragraph

Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jianing ShiDepartment of Information Technology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Xuan WuDepartment of Information Technology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Jiali YuDepartment of Information Technology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Qingli ZhouDepartment of Information Technology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Nonalcoholic steatohepatitis (NASH) is a more advanced stage of Nonalcoholic fatty liver disease (NAFLD) and is particularly common among middle-aged and older adults. NASH-related liver cancer (NALC) is a serious consequence of NASH progression and has become one of the significant causes of global cancer mortality. However, there is currently no comprehensive analysis of the disease burden in this population. This study aims to comprehensively analyze the incidence of NALC among individuals aged 45 and above worldwide from 1990 to 2021 and to project the trends through 2050. Methods: Using the data from the Global Burden of Disease 2021, we analyzed incidence, prevalence, mortality, and disability-adjusted life years (DALYs) among adults ≥ 45 from 1990 to 2021, employing frontier risk analysis and Bayesian modeling to project trends through 2050. Results: In 2021, among adults aged 45 and above, the age-standardized incidence rate of NALC was 1.69 per 100,000, the prevalence rate was 2.01 per 100,000, the mortality rate was 1.66 per 100,000, and DALYs were 36.69 per 100,000 person-years. Since 1990, global indicators have steadily increased, with low-SDI regions showing the highest incidence, mortality, and DALYs, and high-SDI regions having the highest prevalence. Significant regional and national differences were observed. Future projections suggest that while incidence, mortality, and DALYs will initially rise and then decline, prevalence will continue to increase. By 2050, the age-standardized incidence rate of NALC was projected to reach 1.78 per 100,000, and its age-standardized prevalence rate was projected to reach 2.37 per 100,000 person-years. High fasting blood glucose and metabolic risks were the primary contributors to mortality. Conclusion: These findings suggested the urgent need for developing targeted strategies addressing metabolic-related risk factors and implementing standardized screening protocols to mitigate the growing disease burden of NALC in aging populations.

Indexed as

global burdenliver cancernonalcoholic steatohepatitispredictionprevalence

Identifiers

PMID40904774
PMCPMC12401703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.